Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vinblastine · Velban

Small molecule · Inhibitor of tubulin · developed by Lilly

Approved FDA, Nov 1965
1 Registered trials

What is Vinblastine?

Vinblastine is a natural vinca alkaloid that binds tubulin and inhibits microtubule formation, disrupting mitotic spindle assembly and arresting tumor cells in M phase. It is studied in Hodgkin disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Velban
Drug type
Small molecule
Targets
tubulin
Mechanism
Inhibitor of tubulin
Pathways
microtubule formation, mitotic spindle assembly, cell cycle M phase arrest
Therapy area
Oncology
Developer
Lilly
In trials of
MRK, TAK
FDA status
Approved as Velban (November 25, 1965), NDA012665

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02979522 Phase 1/2 Hodgkin Disease Active not recruiting TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hodgkin Disease

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.